Liq­uidia scores on­ly ten­ta­tive ap­proval for Yutrepia due to Ty­va­so ex­clu­siv­i­ty

Liq­uidia’s stock $LQ­DA plum­met­ed near­ly 30% on Mon­day fol­low­ing the com­pa­ny’s an­nounce­ment that while the FDA had grant­ed a ten­ta­tive ap­proval for its tre­pros­tinil in­hala­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER